Top

Published in:

01-01-2010 | Original Article

Treatment of K562 cells with 1,25-dihydroxyvitamin D₃ induces distinct alterations in the expression of apoptosis-related genes BCL2, BAX, BCL_XL, and p21

Authors: Sefa Kizildag, Halil Ates, Servet Kizildag

Published in: Annals of Hematology | Issue 1/2010

Abstract

Apoptosis, or programmed cell death, is a very important phenomenon in cytotoxicity induced by anticancer treatment. 1α,25-Dihydroxyvitamin D₃ (1,25-(OH)₂D₃), the active metabolite of vitamin D, inhibits the growth of multiple types of cancer cells including breast, colon, and prostate cancer cell lines. We studied alterations in the mRNA expression levels of BCL2, BAX, CYC, BCL-XL, and VDR genes in the K562 chronic myeloid leukemia cell line in response to treatment with 1,25-(OH)₂D₃. Morphological observation of K562 cells was evaluated by the staining with Wright's solution. Cell percentage at different phases of the cell cycle was measured, and apoptosis was measured by flow cytometry. The expression levels of the apoptosis-related genes were analyzed by real-time reverse transcription polymerase chain reaction. We found that treatment with 1,25-(OH)₂D₃ down-regulates BCL2 and BCL-XL mRNA expressions, as well as up-regulates expressions of BAX and p21 mRNA. The expression pattern of CYC and VDR genes were not influenced. However, K562 cells treated with 1,25-(OH)₂D₃ caused an arrest of cell cycle progression in G1 phase resulting in a decreased number of cells in the S phase, complemented by an accumulation of cells in the G0–G1 phases. Our data show the modulatory effects of 1,25-(OH)₂D₃ treatment in apoptosis-related genes in K562 cells.

Colston KW, Colston MJ, Feldman D (1981) 1, 25-Dihydroxyvitamin D₃ and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology 108:1083–1086CrossRefPubMed

Abe E, Miyaura C, Sakgami H et al (1981) Differentiation of mouse myeloid leukemia cells induced by 1a, 25-dihydroxyvitamin D₃. Proc Natl Acad Sci U S A 78:4990–4994. doi:10.1073/pnas.78.8.4990 CrossRefPubMed

Elstner E, Linker-Israeli M, Umiel T et al (1995) Combination of a potent 20-epi-vitamin D₃ analog (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. Cancer Res 56:3570–3576

Colston KW, Chander SK, Mackay AG, Coombes RC (1992) Effects of synthetic vitamin D analogs of breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol 44:693–702. doi:10.1016/0006-2952(92)90405-8 CrossRefPubMed

Vandewalle B, Hornez L, Wattez N, Revillion F, Lefebvre J (1995) Vitamin-D₃ derivatives and breast-tumor cell growth: effect on intracellular calcium and apoptosis. Int J Cancer 61:806–811. doi:10.1002/ijc.2910610611 CrossRefPubMed

Colston KW, Mackay AG, James SY, Binderup L (1992) EB1089, a new vitamin D analog that inhibits the growth of breast cancer cells in vivo and in vitro. Biochem Pharmacol 44:2273–2280. doi:10.1016/0006-2952(92)90669-A CrossRefPubMed

Schwartz GG, Hill CC, Oeler TA, Becich MJ, Bahnson RR (1995) 1, 25-Dihydroxy-16–23-yne-vitamin D₃ and prostate cancer cell proliferation in vivo. Urology 46:365–369. doi:10.1016/S0090-4295(99)80221-0 CrossRefPubMed

Chen TC, Schwartz GG, Burnstein KL, Lokeshwar BL, Holick MF (2000) The in vitro evaluation of 25-hydroxyvitamin D₃ and 19-nor-1, 25-dihydroxyvitamin D2 as therapeutics agents for prostate cancer. Clin Cancer Res 6:901–908PubMed

Skarosi S, Abraham C, Bissonette M, Scaglione-Sewel B, Siltrin MD, Brastius TA (1997) 1, 25-Dihydroxyvitamin D₃ stimulates apoptosis in CaCo-2 cells. Gastroenterology 112:A608

10.

Saulenas AM, Cohen SM, Key LL, Winter C, Albert DM (1988) Vitamin D and retinoblastoma: the presence of receptors and inhibition of growth in vitro. Arch Ophthalmol 106:533–535. doi:10.1016/0002-9394(88)90581-8 CrossRefPubMed

11.

Haussler MR, Whitfield GK, Haussler CA et al (1998) The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 13:325–349. doi:10.1359/jbmr.1998.13.3.325 CrossRefPubMed

12.

Issa LL, Leong GM, Eisman JA (1998) Molecular mechanism of vitamin D receptor action. Inflamm Res 47:451–475. doi:10.1007/s000110050360 CrossRefPubMed

13.

Wu G, Fan RS, Li W, Ko T, Brattain MG (1997) Modulation of cell cycle control by vitamin D₃ and its analog, EB1089, in human breast cancer cells. Oncogene 15:1555–1563. doi:10.1038/sj.onc.1201329 CrossRefPubMed

14.

Seol JG, Park WH, Kim ES et al (2000) Effect of a novel vitamin D₃ analog, EB1089 on G1 cell cycle regulatory proteins in HL-60 cells. Int J Oncol 16:315–320PubMed

15.

Liu M, Lee M-H, Cohen M, Bommakanti M, Freedman LP (1996) Transcriptional activation of the cdk inhibitor p21 by vitamin D₃ leads to the induced differentiation of the myelocytic cell line U937. Genes Dev 10:142–153. doi:10.1101/gad.10.2.142 CrossRefPubMed

16.

Jensen SS, Madsen MW, Lukas J, Binderup L, Bartek J (2001) Inhibitory effects of dihydroxyvitamin D₃ on G1-S phase controlling machinery. Mol Endocrinol 15:1370–1380. doi:10.1210/me.15.8.1370 CrossRefPubMed

17.

Reitsma PH, Rothberg PG, Astrin SM, Trial J, Bar-Shavit Z, Hall A, Teitelbaum SL, Kahn AJ (1983) Regulation of myc gene expression in HL-60 leukaemia cells by a vitamin D metabolite. Nature 306:492–494. doi:10.1038/306492a0 CrossRefPubMed

18.

Kasten MM, Giordano A (1998) pRb and the cdks in apoptosis and the cell cycle. Cell Death Differ 5:132–140. doi:10.1038/sj.cdd.4400323 CrossRefPubMed

19.

Mørk Hansen C, Hamberg KJ, Binderup E, Binderup L (2000) Seocalcitol (EB 1089): a vitamin D analogue of anti-cancer potential. Background, design, synthesis, pre-clinical and clinical evaluation. Current Pharmaceutical Design 6:881–906

20.

van den Bemd GJCM, Pols HAP, van Leeuwen JPTM (2000) Anti-tumor effects of 1, 25-dihydroxyvitamin D₃ and vitamin D analogs. Curr Pharm Des 6:717–732. doi:10.2174/1381612003400498 CrossRefPubMed

21.

Feldman D, Zhao X-Y, Krishnan AV (2000) Vitamin D and prostate cancer. Endocrinology 141:5–9. doi:10.1210/en.141.1.5 CrossRefPubMed

22.

Lozzio BB, Lozzio CB (1977) Properties of the K562 cell line derived from a patient with chronic myeloid leukemia. Int J Cancer 19:136–143. doi:10.1002/ijc.2910190119 CrossRefPubMed

23.

Moore DC, Carter DL, Bhandal AK, Studzinski GP (1991) Inhibition by 1, 25 dihydroxyvitamin D₃ of chemically induced erythroid differentiation of K562 leukemia cells. Blood 77:1452–1461PubMed

24.

Naveilhan P, Berger F, Haddad K et al (1994) Induction of glioma cell death by 1, 25(OH) 2 vitamin D₃: towards an endocrine therapy of brain tumors. J Neurosci Res 37:271–277. doi:10.1002/jnr.490370212 CrossRefPubMed

25.

Diaz GD, Paraskeva C, Thomas MG, Binderup L, Hague A (2000) Apoptosis is induced by the active metabolite of vitamin D₃ and its analog EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res 60:2304–2312PubMed

26.

Mathiasen IS, Lademann U, Jaattela M (1999) Apoptosis induced by vitamin D compounds in breast cancer is inhibited by Bcl-2 but doesn't involve known caspases or p53. Cancer Res 59:4848–4856PubMed

27.

Miller GJ, Stapleton GE, Ferrara JA, Lucia MS, Pfister S et al (1992) The human prostatic carcinoma cell line LNCaP expresses biologically active, specific receptors for 1 alpha, 25-dihydroxyvitamin D₃. Cancer Res 52:515–520PubMed

28.

Mork-Hansen C, Frandsen TL, Brunner N, Binderup L (1994) 1α-25-Dihydroxyvitamin D₃ inhibits the invasive potential of human breast cancer cells in vitro. Clin. Exp. Metas. 12:195–202. doi:10.1007/BF01753887 CrossRef

29.

Colston KW, Hansen C (2002) Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer 9:45–59. doi:10.1677/erc.0.0090045 CrossRefPubMed

30.

Chen S, Xue Y, Zhang X, Wu Y, Pan J, Wang Y, Ceng J (2005) A new human acute monocytic leukemia cell line SHI-1 with t(6;11)(q27;q23) gene alteration and high tumorigenicity in nude mice. Hematologia 90:766–775

31.

Park WH, Seol JG, Kim ES, Jung CW, Lee CC, Binderup L, Koeffler HP, Kim BK, Lee YY (2000) Cell cycle arrest induced by vitamin D₃ analog EB1089 in NCI-H929 myeloma cells is associated with induction of the cyclin-dependent kinase inhibitor p27. Exp Cell Res 254:279–286. doi:10.1006/excr.1999.4735 CrossRefPubMed

32.

Zhang F, Rathod B, Jones JB, Wang QM, Bernhard E, Godyn JJ, Studzinski GP (1996) Increased stringency of the 1, 25-dihydroxyvitamin D₃-induced G1 to S phase block in polyploid HL60 cells. J Cell Physiol 168:18–25. doi:10.1002/(SICI)1097-4652(199607)168:1<18::AID-JCP3>3.0.CO;2-B CrossRefPubMed

33.

Zhang F, Godyn JJ, Uskokovic M, Binderup L, Studzinski GP (1994) Monocytic differentiation of HL60 cells induced by potent analogs of vitamin D₃ precedes the G1/G0 phase cell cycle block. Cell Prolif 27:643–654. doi:10.1111/j.1365-2184.1994.tb01379.x CrossRef

34.

Pirianov G, Colston KW (2001) Interaction of vitamin D analogs with signaling pathways leading to active cell death in breast cancer cells. Steroids 66:309–318. doi:10.1016/S0039-128X(00)00201-4 CrossRefPubMed

35.

Narvaez CJ, Welsh J (2001) Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells. J Biol Chem 276:9101–9107. doi:10.1074/jbc.M006876200 CrossRefPubMed

36.

Park WH, Seol JG, Kim ES, Hyun JM, Jung CW, Lee CC, Binderup L, Koeffler HP, Kim BK, Lee YY (2000) Induction of apoptosis by vitamin D₃ analogue EB 1089 in NCI-H929 myeloma cells via activation of caspase and MAP kinase. Br J Haematol 109:576–583. doi:10.1046/j.1365-2141.2000.02046.x CrossRefPubMed

37.

Blutt SE, McDonnell TJ, Polek TC, Weigel NL (2000) Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology 141:10–17. doi:10.1210/en.141.1.10 CrossRefPubMed

38.

Yang JY, Liu X, Bhalla K, Naekyung Kim C, Ibrado AM, Cai J, Peng T-I, Jones DP, Wang X (1997) Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondrial blocked. Science 275:1129–1132. doi:10.1126/science.275.5303.1129 CrossRefPubMed

Title: Treatment of K562 cells with 1,25-dihydroxyvitamin D3 induces distinct alterations in the expression of apoptosis-related genes BCL2, BAX, BCLXL, and p21
Authors: Sefa Kizildag
Halil Ates
Servet Kizildag
Publication date: 01-01-2010
Publisher: Springer-Verlag
Published in: Annals of Hematology / Issue 1/2010
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-009-0766-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2010

The same genetic defect in three Tunisian families with Bernard Soulier syndrome: a probable founder Stop mutation in GPIbbeta

Screening of platelet concentrates for bacterial contamination: spectrum of bacteria detected, proportionof transfused units, and clinical follow-up

Prevalence and analysis of t(14;18) and t(11;14) chromosomal translocations in healthy Indian population

Increased bone resorption is implicated in the pathogenesis of bone loss in hemophiliacs: correlations with hemophilic arthropathy and HIV infection

Lenalidomide in 5q minus myelodysplastic syndrome: how long is enough?

Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials